[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Absci Corp (ABSI)

Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,697,805
  • Shares Outstanding, K 155,905
  • Annual Sales, $ 2,800 K
  • Annual Income, $ -115,180 K
  • EBIT $ -117 M
  • EBITDA $ -105 M
  • 60-Month Beta 2.44
  • Price/Sales 568.50
  • Price/Cash Flow N/A
  • Price/Book 9.23

Options Overview Details

View History
  • Implied Volatility 135.78% (+10.34%)
  • Historical Volatility 146.86%
  • IV Percentile 81%
  • IV Rank 34.67%
  • IV High 254.89% on 03/24/26
  • IV Low 72.59% on 12/24/25
  • Expected Move (DTE 19) 2.22 (20.37%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 2,990
  • Volume Avg (30-Day) 3,710
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 61,446
  • Open Int (30-Day) 59,292
  • Expected Range 8.67 to 13.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.17
  • Number of Estimates 2
  • High Estimate $-0.16
  • Low Estimate $-0.19
  • Prior Year $-0.24
  • Growth Rate Est. (year over year) +29.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.08 +114.37%
on 05/27/26
11.36 -4.14%
on 06/26/26
+5.61 (+106.25%)
since 05/26/26
3-Month
2.71 +301.85%
on 03/30/26
11.36 -4.14%
on 06/26/26
+8.01 (+278.13%)
since 03/26/26
52-Week
2.24 +386.16%
on 03/12/26
11.36 -4.14%
on 06/26/26
+8.18 (+301.85%)
since 06/26/25

Most Recent Stories

More News
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement...

ABSI : 10.89 (+6.66%)
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted...

ABSI : 10.89 (+6.66%)
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the Future of AI Drug Discovery

MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a bio-native AI company, today announced that President and Chief Executive Officer Dr. Jennifer Bath will join a virtual panel hosted by Jones,...

ABSI : 10.89 (+6.66%)
HYFT : 1.5800 (+3.95%)
Absci to Participate in Upcoming Investor Conferences

VANCOUVER, Wash. and NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 10.89 (+6.66%)
Absci Q1 Earnings Call Highlights

Absci (NASDAQ:ABSI) executives on Wednesday outlined a “data-rich” 2026 anchored by multiple clinical updates for ABS-201, the company’s anti-prolactin receptor antibody being studied in androgenetic...

ABSI : 10.89 (+6.66%)
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results

Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling...

ABSI : 10.89 (+6.66%)
Absci Reports Tomorrow With Investors Still Waiting for the AI Drug Platform to Prove Itself

Barchart Research What to Expect from ABSI Earnings ABSI Generated May 6, 2026 Current Price $5.95 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 7.52% Absci Reports Tomorrow With Investors...

ABSI : 10.89 (+6.66%)
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, Wash. and NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 10.89 (+6.66%)
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026

VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 10.89 (+6.66%)
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative...

ABSI : 10.89 (+6.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Absci Corporation is a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design. Absci Corporation is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 12.91
2nd Resistance Point 12.14
1st Resistance Point 11.51
Last Price 10.89
1st Support Level 10.11
2nd Support Level 9.34
3rd Support Level 8.71

See More

52-Week High 11.36
Last Price 10.89
Fibonacci 61.8% 7.88
Fibonacci 50% 6.80
Fibonacci 38.2% 5.72
52-Week Low 2.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.